MacroGenics (MGNX) PT Raised to $37 at Wedbush on MARGENZA Approval

Go back to MacroGenics (MGNX) PT Raised to $37 at Wedbush on MARGENZA Approval

Pre-Open Stock Movers 12/17: (XSPA) (MGNX) (RAD) (ROKU) Higher; (QTT) (PHAT) (ABM) Lower (more...)

December 17, 2020 9:22 AM EST

Today's Pre-Open Stock Movers:

XpresSpa Group, Inc. (Nasdaq: XSPA) 30% HIGHER; the company announced its XpresCheck subsidiary had entered into a national agreement with United Airlines to offer COVID-19 testing services starting with Newark Liberty International Airport (EWR) and Denver International Airport (DEN).

MacroGenics, Inc. (Nasdaq: MGNX) 19.3% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic... More

MacroGenics (MGNX) PT Raised to $14 at Barclays

December 17, 2020 4:38 AM EST

Barclays analyst Peter Lawson raised the price target on MacroGenics (NASDAQ: MGNX) to $14.00 (from $8.00) while maintaining a Underweight rating.... More

After-Hours Movers 12/16: (MGNX) (SELB) (ROKU) Higher; (QTT) (ABM) (GSX) Lower (more...)

December 16, 2020 5:39 PM EST

Today's After-Hours Stock Movers:

MacroGenics, Inc. (Nasdaq: MGNX) 19.3% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is the first product approved from MacroGenics promising pipeline. The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

Selecta Biosciences (NASDAQ: SELB)... More

Macrogenics (MGNX) Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

December 16, 2020 4:33 PM EST

(Updated - December 16, 2020 5:23 PM EST)

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is the first product approved from MacroGenics promising pipeline. The approval was based on safety and efficacy results... More